The latest price target for Citius Pharma (NASDAQ:CTXR) was reported by HC Wainwright & Co. on November 12, 2024. The analyst firm set a price target for $4.00 expecting CTXR to rise to within 12 months (a possible 2400.00% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Citius Pharma (NASDAQ:CTXR) was provided by HC Wainwright & Co., and Citius Pharma reiterated their buy rating.

There is no last upgrade for Citius Pharma

There is no last downgrade for Citius Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a reiterated with a price target of $4.00 to $4.00. The current price Citius Pharma (CTXR) is trading at is $0.16, which is out of the analyst’s predicted range.